{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:49:48Z","timestamp":1787003388131,"version":"build-2736575974"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1038\/s41575-025-01170-9","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T11:20:22Z","timestamp":1767957622000},"page":"115-116","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pancreatic cancer: advances in immunology, translational analyses and therapeutic paradigms"],"prefix":"10.1038","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8076-9199","authenticated-orcid":false,"given":"Eileen M.","family":"O\u2019Reilly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"key":"1170_CR1","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/s41586-024-08508-4","volume":"639","author":"Z Sethna","year":"2025","unstructured":"Sethna, Z. et al. RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. Nature 639, 1042\u20131051 (2025).","journal-title":"Nature"},{"key":"1170_CR2","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas, L. A. et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618, 144\u2013150 (2023).","journal-title":"Nature"},{"key":"1170_CR3","doi-asserted-by":"publisher","first-page":"3648","DOI":"10.1038\/s41591-025-03876-4","volume":"31","author":"ZA Wainberg","year":"2025","unstructured":"Wainberg, Z. A. et al. Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results. Nat. Med. 31, 3648\u20133653 (2025).","journal-title":"Nat. Med."},{"key":"1170_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-60808-z","volume":"16","author":"JJ Knox","year":"2025","unstructured":"Knox, J. J. et al. Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial. Nat. Commun. 16, 5919 (2025).","journal-title":"Nat. Commun."},{"key":"1170_CR5","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/s41591-024-03362-3","volume":"31","author":"AM Varghese","year":"2025","unstructured":"Varghese, A. M. et al. Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival. Nat. Med. 31, 466\u2013477 (2025).","journal-title":"Nat. Med."},{"key":"1170_CR6","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.1200\/JCO-25-00436","volume":"43","author":"JJ Knox","year":"2025","unstructured":"Knox, J. J. et al. PASS-01: randomized phase II trial of modified FOLFIRINOX versus gemcitabine\/nab-paclitaxel and molecular correlatives for previously untreated metastatic pancreatic cancer. J. Clin. Oncol. 43, 3355\u20133368 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1170_CR7","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1016\/S1470-2045(25)00363-8","volume":"26","author":"QP Janssen","year":"2025","unstructured":"Janssen, Q. P. et al. Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial. Lancet Oncol. 26, 1346\u20131356 (2025).","journal-title":"Lancet Oncol."},{"key":"1170_CR8","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1200\/JCO.21.02233","volume":"40","author":"E Versteijne","year":"2022","unstructured":"Versteijne, E. et al. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial. J. Clin. Oncol. 40, 1220\u20131230 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1170_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01685-X","author":"M Reni","year":"2025","unstructured":"Reni, M. et al. Preoperative mFOLFIRINOX versus PAXG for stage I\u2013III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the first randomisation analysis of a randomised, open-label, 2 x 2 factorial phase 3 trial. Lancet https:\/\/doi.org\/10.1016\/S0140-6736(25)01685-X (2025).","journal-title":"Lancet"},{"key":"1170_CR10","first-page":"132","volume":"39","author":"AD Cox","year":"2025","unstructured":"Cox, A. D. & Der, C. J. \u201cUndruggable KRAS\u201d: druggable after all. Genes Dev. 39, 132\u2013162 (2025).","journal-title":"Genes Dev."}],"container-title":["Nature Reviews Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41575-025-01170-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-025-01170-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-025-01170-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T13:03:00Z","timestamp":1770037380000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41575-025-01170-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1170"],"URL":"https:\/\/doi.org\/10.1038\/s41575-025-01170-9","relation":{},"ISSN":["1759-5045","1759-5053"],"issn-type":[{"value":"1759-5045","type":"print"},{"value":"1759-5053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]},"assertion":[{"value":"9 January 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.M.O. reports research funding to institution from Genentech\/Roche, BioNTech, AstraZeneca, Arcus, Elicio Therapeutics, Parker Institute, NIH\/NCI, Digestive Care, Break Through Cancer, Agenus, Amgen and Revolution Medicines; consulting\/data and\u00a0safety monitoring board, uncompensated from Arcus, Amgen, AstraZeneca, Ability Pharma, Alligator BioSciences, Pfizer, Agenus, BioNTech, Ipsen, Ikena, Merck, Immuneering, Moma Therapeutics, Novartis, Astellas, BMS, Revolution Medicines, Regeneron and Tango Therapeutics; travel\u00a0expenses for BioNTech and Arcus; and other for American Association of Cancer Research (AACR), American Society of Clinical Oncology (ASCO), Imedex, Research To Practice, Stand Up To Cancer (SU2C) and NIH\/NCI Cancer Center Support Grant\/Core Grant P30 CA008748 and NCI\/NIH P50 CA257881-01A1.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}